Type B meeting scheduled with FDA Division of Cardiology and Nephrology
Company plans to discuss new clinical data that may inform a potential NDA submission
Read more at prnewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Type B meeting scheduled with FDA Division of Cardiology and Nephrology
Company plans to discuss new clinical data that may inform a potential NDA submission
Read more at prnewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| MITO | 0.3200 | -0.0044 | -1.36% |
| Stealth Biotherapeutics Corp ADR | |||